Aytu BioPharma just printed a quarter that crystallized the trade. Q3 FY2026 net revenue of $12.4M was down 32.7% from $18.5M a year earlier; the new EXXUA CNS product contributed $2.4M of that, the ADHD Portfolio fell 40.9% to $9.1M, and the Pediatric Portfolio collapsed 69.9% to $0.9M - the company is now in the middle of swapping its revenue base from a slowly declining ADHD franchise (now under generic attack) onto a freshly launched CNS product whose second full quarter of selling was the entirety of EXXUA's contribution. The GAAP operating result swung from a $2.4M operating profit a year ago to a $4.1M operating loss; nine-month operating loss widened to $7.5M from $0.2M. EXXUA's $2.4M quarterly run-rate, annualized to roughly $10M, is not yet large enough to absorb the decline in the legacy book - and the market has decided what to do with that math. The stock closed August 14, 2026 at $2.38, valuing the company at $25.6M of market capitalization on $56.6M of trailing-twelve-month revenue, an enterprise value near $20.8M after netting $4.9M of net cash and $22.0M of total debt principal, or 0.37x EV/TTM revenue. The question the next four quarters have to answer is whether EXXUA's run-rate compounds or stalls.